The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 27, 2007
Filed:
Nov. 20, 2002
Andrew Thomas Bach, Summit, NJ (US);
Prasad Koteswara Kapa, Parsippany, NJ (US);
George Tien-san Lee, Towaco, NJ (US);
Eric M. Loesser, Scotch Plains, NJ (US);
Michael Lloyd Sabio, Randolph, NJ (US);
James Lawrence Stanton, Charlestown, MA (US);
Thalaththani Ralalage Vedananda, Shrewsbury, MA (US);
Andrew Thomas Bach, Summit, NJ (US);
Prasad Koteswara Kapa, Parsippany, NJ (US);
George Tien-San Lee, Towaco, NJ (US);
Eric M. Loesser, Scotch Plains, NJ (US);
Michael Lloyd Sabio, Randolph, NJ (US);
James Lawrence Stanton, Charlestown, MA (US);
Thalaththani Ralalage Vedananda, Shrewsbury, MA (US);
Novartis AG, Basel, CH;
Abstract
Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPARα and PPARγ receptors.